XML 46 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Segment Information
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company operates its business and reports its results through three operating and reportable segments: dispensary, patient services, and clinical trials & other in accordance with ASC 280. See Note 2 for a summary of the Company’s policy on segment information.
Summarized financial information for the Company’s segments is shown in the following tables:
(in thousands)Three Months Ended March 31,
20232022
Revenue
Patient services$50,273 $35,057 
Dispensary24,240 18,679 
Clinical trials & other1,679 1,425 
Consolidated revenue$76,192 $55,161 
Direct costs
Patient services$42,814 $27,378 
Dispensary19,145 15,324 
Clinical trials & other134 137 
Total segment direct costs$62,093 $42,839 
Depreciation expense
Patient services$406 $250 
Dispensary16 — 
(in thousands)Three Months Ended March 31,
20232022
Clinical trials & other— 47 
Total segment depreciation expense$422 $297 
Amortization of intangible assets
Patient services$675 $621 
Dispensary— — 
Clinical trials & other52 53 
Total segment amortization$727 $674 
Operating income
Patient services$6,378 $6,808 
Dispensary5,079 3,355 
Clinical trials & other1,493 1,188 
Total segment operating income$12,950 $11,351 
Goodwill impairment charges
Patient services$16,235 $— 
Dispensary— — 
Clinical trials & other632 — 
Total impairment charges$16,867 $— 
Selling, general and administrative expense$28,830 $29,806 
Non-segment depreciation and amortization120 16 
Total consolidated operating loss$(32,867)$(18,471)
(in thousands)March 31, 2023December 31, 2022
Assets   
Patient services$70,241 $64,869 
Dispensary9,872 7,194 
Clinical trials & other11,471 11,496 
Non-segment assets143,049 178,106 
Total assets$234,633 $261,665